Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.

Dmitriy ZamarinSven WalderichAliya HollandQin ZhouAlexia E IasonosJean M TorrisiTaha MerghoubLewis F ChesebroughAutumn S McdonnellJacqueline M GallagherYanyun LiTravis J HollmannRachel N GrishamCourtney L ErskineMathew S BlockKeith L KnutsonRoisin E O'CearbhaillCarol AghajanianJason A Konner

Published in: Journal for immunotherapy of cancer (2021)

Combination of TPIV200 and durvalumab was safe and elicited robust FRα-specific T cell responses in all patients. Unexpectedly durable survival in this heavily pretreated population highlights the need to investigate the impact of FRα vaccination on the OC biology post-treatment.

Keyphrases

end stage renal disease
ejection fraction
prognostic factors
patient reported outcomes
study protocol